Bavencio IV infusion 200mg, manufactured by Merck Biopharma, contains Avelumab (genetical recombination), a fully human monoclonal antibody (PD-L1 blocking antibody). It is indicated for the treatment of metastatic Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma. This 200mg 10mL 1 bottle has a YJ code of 4291438A1022.
Bavencio IV infusion 200mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →